OAB Survey – Confidential

Mirabegron prescription pattern survey Alembic Pharmaceuticals Ltd

Survey No AL- BLADMIR-22-001 Version No. 1.0 Date 27-Apr-22

Doctor Name Institute affiliation Speciality

Address

Contact no.

The Information provided in this document is strictly confidential and is available for review to
Alembic Pharmaceuticals only. No disclosure should take place without written authorization
from Alembic Pharmaceuticals Pvt. Ltd.

Company Representative Name: ……………………………………………………………………………

Title:……………………………………………………………………………………….………………………………

Address:
Alembic Pharmaceuticals Limited,
2nd Floor, Prime Corporate Park
Behind ITC Grand Maratha Sheraton,
Sahar Road, Andheri East, Mumbai,
Maharashtra 400099
 OAB Survey – Confidential
Mirabegron prescription pattern survey Alembic Pharmaceuticals Ltd

Survey No AL- BLADMIR-22-001 Version No. 1.0 Date 27-Apr-22

1. What percentages of OAB patients do you see daily in your clinical practice?

5%
5-10%
10-20%
>20%

2. What percentages of Female OAB patients do you see daily in your clinical
practice?

5%
5-10%
10-20%
>20%

3. Are you satisfied with the current treatment available for OAB?

Yes
No

4. How long do you prescribe Mirabegron to OAB patients?

1-3 months
3-6 months
6-12 months
>12 months
 OAB Survey – Confidential
Mirabegron prescription pattern survey Alembic Pharmaceuticals Ltd

Survey No AL- BLADMIR-22-001 Version No. 1.0 Date 27-Apr-22

5. What percentages of your patients discontinued the anticholinergic therapy?

Months Discontinuation percentage rate

<25% 25-50% 50-70% >70%

1 month

3 months

5 months

6. What are the reasons behind the discontinuation of anticholinergic therapy?

Limited efficacy
Side effects
High Cost of therapy

7. What are the treatment options do you consider for patients who do not respond
to Anticholinergic therapy or not suitable for anticholinergic therapy?

Wait and watch

Mirabegron
Surgery
Bladder injections

Nerve stimulation

8. Have you ever used Mirabegron as a first line therapy in your OAB patients?
Yes

No
 OAB Survey – Confidential
Mirabegron prescription pattern survey Alembic Pharmaceuticals Ltd

Survey No AL- BLADMIR-22-001 Version No. 1.0 Date 27-Apr-22

9. If yes ----- then how many percentages of patients of OAB respond to Mirabegron
as a first line therapy?

< 25

25-50

50-75

>75

10. What factors do you consider while prescribing Mirabegron?

Rate on scale of 0 to 5 ( 0 least

Deciding Factors to prescribe Mirabegron important , 5 most important)

Naïve patient 0 1 2 3 4 5

Treatment failure with Anticholinergics 0 1 2 3 4 5

Non responding to Anticholinergics 0 1 2 3 4 5

Poor adherence to anticholinergics 0 1 2 3 4 5

Comorbid conditions with OAB 0 1 2 3 4 5

Elderly patient with OAB 0 1 2 3 4 5

Relatively younger patient with OAB 0 1 2 3 4 5

Safety profile 0 1 2 3 4 5

Long term maintenance therapy 0 1 2 3 4 5

Any another, kindly specify

 OAB Survey – Confidential
Mirabegron prescription pattern survey Alembic Pharmaceuticals Ltd

Survey No AL- BLADMIR-22-001 Version No. 1.0 Date 27-Apr-22

11. Which are the factors do you consider to begin with Mirabegron & Solifenacin
combination therapy?

Deciding factors to prescribe combination Rate on scale of 0 to 5 ( 0 least

therapy important , 5 most important)

Treatment failure with Anticholinergics/B3

agonist 0 1 2 3 4 5

Non responding to Anticholinergics/B3 agonist 0 1 2 3 4 5

Poor adherence to anticholinergics 0 1 2 3 4 5

Severe OAB symptoms 0 1 2 3 4 5

Comorbid conditions with OAB 0 1 2 3 4 5

Elderly patient with OAB 0 1 2 3 4 5

Safety profile 0 1 2 3 4 5

Any other reason please specify.

12. Which step down option do you prefer for long-term maintenance therapy in your OAB
patients who are already on Mirabegron & Solifenacin combination therapy? (tick one
option only)

Mirabegron monotherapy
Solifenacin monotherapy
Continue with reduced dose of combination therapy

13. Have your female patients has earlier consulted with any other speciality before
approaching specialist?

Yes

No
 OAB Survey – Confidential
Mirabegron prescription pattern survey Alembic Pharmaceuticals Ltd

Survey No AL- BLADMIR-22-001 Version No. 1.0 Date 27-Apr-22

14. What would be the order of preference for first consultation of female OAB
patients towards a speciality?

Speciality % Patients

<25% 25-50% 50-70% >70%

CP

Gynec

GPs

Surgeons

Urologist

Doctor name: ……………………………………………………………………………………………………………

Doctor Signature with Stamp: …………………………………………………………………………………………

Date: ………………………………………………………………………………………………………………………

Place: ………………………………………………………………………………………………………………………